| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Kymera Therapeutics (NASDAQ:KYMR) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 3 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 2 | 2 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Kymera Therapeutics, revealing an average target of $53.0, a high estimate of $56.00, and a low estimate of $47.00. Observing a 42.28% increase, the current average has risen from the previous average price target of $37.25.
In examining recent analyst actions, we gain insights into how financial experts perceive Kymera Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jeff Jones | Oppenheimer | Announces | Outperform | $53.00 | - |
| Srikripa Devarakonda | Truist Securities | Raises | Buy | $54.00 | $41.00 |
| Edward Tenthoff | Piper Sandler | Raises | Overweight | $56.00 | $39.00 |
| Eric Joseph | JP Morgan | Raises | Overweight | $47.00 | $34.00 |
| Bradley Canino | Stifel | Raises | Buy | $55.00 | $35.00 |
To gain a panoramic view of Kymera Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Kymera Therapeutics analyst ratings.
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining Kymera Therapeutics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 196.7% as of 31 December, 2023, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Kymera Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -30.01% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -3.64%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Kymera Therapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -2.55% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.21.
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: KYMR
